Actively Recruiting
Evaluating ARIKAYCE Inhalation with Standard Antibiotics for Mycobacterium xenopi Lung Infection Treatment
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2026-10-27
190
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatment options for Mycobacterium xenopi lung disease, a condition that is challenging to treat and often affects patients with chronic lung diseases or weakened immune systems. The current treatment lasts about 18 months, based on sputum conversion, but outcomes remain poor. This study investigates adding amikacin liposome inhalation suspension ARIKAYCE4 to the standard treatment to improve results, building on previous research where ARIKAYCE4 showed promising effects against similar lung infections. Participants will be randomly assigned to one of two groups one receiving standard treatment with rifampicin, ethambutol, and clarithromycin, and the other receiving these same drugs plus ARIKAYCE4 inhalation for the first six months. The treatment duration depends on sputum conversion, with therapy continuing until 12 months after conversion, typically totaling 18 months. ARIKAYCE4 is designed to deliver amikacin directly to the lungs, increasing drug uptake by immune cells and limiting exposure to the rest of the body. During the study, participants will undergo assessments to monitor sputum conversion rates at three months as the primary outcome. Secondary outcomes include time to culture conversion and mortality rates at 12 and 24 months. The study uses a randomized and triple-masked design to compare the added effect of ARIKAYCE4 with standard care. Participants will receive regular evaluations throughout the treatment period to track safety and effectiveness until study completion in December 2030.
CONDITIONS
Brief Title
Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection
Research Team
C
Claire ANDREJAK, Pr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here